Highest-materiality recent filing
Vaxart files preliminary proxy; urges support for board nominees amid dissident challenge
Annual meeting set for July 16, 2026; preliminary proxy filed with SEC.
Vaxart reports Q1 net income $5.2M; COVID-19 sentinel data expected Q2 2026
Q1 2026 net income $5.2M ($0.02/sh) vs net loss ($15.6M) in Q1 2025.
Vaxart enters $25M equity purchase agreement with Lincoln Park Capital
Vaxart can sell up to $25M of common stock to Lincoln Park over 24 months at its discretion.
Vaxart reports FY2025 net income of $16.3M vs loss; revenue $237.3M; cash runway into Q2 2027
Net income $16.3M ($0.07 EPS) vs net loss $66.9M ($0.33 loss) in FY2024.
Revenue $72.4M (vs $4.9M Q3 2024) from BARDA contract; net loss $8.1M ($0.04 EPS) vs $14.1M loss.
Dynavax pays $25M upfront license fee and $5M equity (11.1M shares at $0.45/share) for worldwide rights to Vaxart's oral COVID-19 vaccine.
BARDA narrows Vaxart COVID vaccine pact; 5,000-subject follow-up continues
Received Follow-Up Notice on Oct 8: BARDA intends to delimit Project Agreement excluding paused work.
Vaxart receives Nasdaq delisting notice after withdrawing reverse stock split
On Sept 19, 2025, Nasdaq notified Vaxart that its securities will be delisted due to noncompliance with the Panel's conditions.
Nasdaq Hearings Panel decision on Aug 27, 2025 grants continued listing with three conditions.
Vaxart Q2 rev $39.7M; norovirus antibodies up 141%; COVID trial stopped at 5K enrolled
Q2 2025 revenue $39.7M (vs $6.4M YoY); net loss $15.0M ($0.07/sh) vs $16.5M ($0.09/sh).
Vaxart receives stop work order from BARDA on Phase 2b oral COVID-19 vaccine trial
ATI/BARDA directed Vaxart to stop all work on Project Agreement RRPV-24-04-NGVx-003 for oral COVID-19 vaccine.
Vaxart delisted from Nasdaq, begins trading on OTCQX after bid price failure
Nasdaq delisted VXRT for non-compliance with minimum bid price requirement (Rule 5550(a)(2)).
Vaxart receives Nasdaq delisting notice; trading suspended July 8, 2025
Nasdaq Staff determined to delist VXRT common stock for failing to meet $1.00 minimum bid price requirement.
Vaxart shareholders reject reverse stock split and say-on-pay proposals
Reverse stock split amendment failed with 63.6M for, 91.9M against; company evaluating next steps.
Second-gen constructs showed 141% increase in GI.1 and 94% increase in GII.4 NBAA titers vs first-gen at high dose, statistically significant.
Vaxart adjourns annual meeting to June 13 due to insufficient votes for reverse stock split
Meeting adjourned from June 2 to June 13, 2025 at 8:30 a.m. PT to solicit more votes.
First patient dosed in 10,000-participant portion of Phase 2b trial for oral pill COVID-19 vaccine candidate.
Vaxart urges stockholders to vote FOR reverse stock split; Board commits to 1-for-20 high end
Annual Meeting adjourned to June 2, 2025; vote deadline for reverse split is June 1, 2025.
Annual meeting adjourned to June 2, 2025 at 8:30 a.m. PT; proxies representing ~67% of shares already submitted.
Vaxart narrows reverse split range to max 1-for-20; proposes proportional authorized share reduction
Board narrowed proposed reverse split range: no ratio higher than 1-for-20.
Vaxart gets BARDA approval to start dosing 10,000 participants in Phase 2b COVID vaccine trial
BARDA approved initiation of dosing in 10,000-participant Phase 2b trial of oral COVID-19 vaccine.
Vaxart Q1 net loss $15.6M; COVID-19 Phase 2b screening underway, CFO appointed
Net loss $15.6M ($0.07/shr) vs $24.4M ($0.14) prior year; revenue $20.9M from BARDA contract (vs $2.2M).
Vaxart appoints Jeroen Grasman as CFO, replaces Phillip Lee
CFO Phillip Lee resigns effective upon appointment of successor; no disagreement; remains as non-executive employee through June 1, 2025.
Vaxart addresses reverse split FAQs; vote May 21 to avoid Nasdaq delisting at $0.42/share
Stock closed at $0.42 on May 9, 2025, below Nasdaq's $1.00 minimum bid requirement.
Vaxart updates: BARDA stop-work lifted, norovirus enrollment done, reverse split proposal
BARDA stop-work order on COVID-19 Phase 2b trial lifted April 24, 2025; 10,000-participant portion pending BARDA approval.
BARDA lifts stop work order on Vaxart norovirus trial; 10,000-participant screening to resume
Stop work order lifted April 24, 2025 by ATI/BARDA; company may resume incurring costs.
Vaxart reports FY2024 net loss $66.9M, revenue $28.7M; initiates Phase 1 norovirus trial
Net loss $66.9M ($0.33/sh) vs $82.5M in 2023; revenue $28.7M (up from $7.4M).
Vaxart enters $50M at-the-market equity offering agreement with Citizens JMP and B. Riley
Company may sell up to $50M of common stock at market prices via ATM facility.
Vaxart initiates Phase 1 trial for oral norovirus vaccine; topline data expected mid-2025
Phase 1 open-label dose-ranging trial evaluating second-generation oral norovirus pill vaccine vs first-generation constructs.
Vaxart receives stop work order from BARDA on Project Agreement; work halted for 90 days
Received stop work order from ATI (BARDA) on Feb 21, 2025 for all efforts under Project Agreement RRPV-24-04-NGVx-003.
Vaxart secures $105.9M BARDA funding increase; Phase 2b trial to test KP.2 vaccine vs mRNA
Total BARDA funding for the Phase 2b trial now $240.1M, up from $134.2M.
DSMB recommends Vaxart's COVID-19 Phase 2b trial proceed; norovirus Phase 1 in H1 2025
DSMB recommends Phase 2b proceed after review of 30-day safety data from 400-participant sentinel cohort.
Vaxart receives second 180-day Nasdaq extension to cure bid price deficiency until June 30, 2025
Nasdaq notified Vaxart on Dec 31, 2024 of an additional 180-day compliance period to meet the $1.00 minimum bid price requirement.
Vaxart completes sentinel cohort enrollment in Phase 2b oral COVID vaccine trial
Sentinel cohort of 400 participants randomized 1:1 to Vaxart's oral pill vaccine or approved mRNA comparator.
Vaxart Q3 net loss narrows to $14.1M; COVID Phase 2b sentinel enrollment near completion
Q3 revenue $4.9M (up from $2.1M YoY) from BARDA contracts; net loss per share $0.06 vs $0.11.
Modification No. 3 increased total estimated ceiling to ~$456.1M (+$3.2M) and allotted funding to ~$96.5M (+$30.8M).
Vaxart Q2 net loss narrows to $16.5M; BARDA award up to $453M for COVID Phase 2b
Net loss per share $0.09 vs $0.16 YoY; revenue $6.4M (from $1.4M) on BARDA contract.
Vaxart receives Nasdaq notice of non-compliance with $1.00 minimum bid price
Notice received July 2, 2024; bid price below $1.00 for 30 consecutive days (May 17–July 1, 2024).
On May 13, 2025, the Company announced that its Board of Directors had appointed Jeroen Grasman to serve as the Company’s Chief Financial Officer and as the Company’s Principal Accounting Officer and Principal Financial Officer, effective as of May 19, 2025.
On May 12, 2025, Phillip Lee notified the Company of his intention to resign as the Chief Financial Officer of Vaxart, Inc. (the “Company”) and as the Company’s Principal Accounting Officer and Principal Financial Officer, effective upon the appointment of a new Chief Financial Officer.
Robert A. Yedid resigned from the Board and any committees of the Board, effective January 28, 2025
the Board appointed Kevin Finney to serve on the Board, effective January 28, 2025
In connection with Mr. Lo’s appointment, Michael J. Finney, Ph.D. will step down as the Company’s Interim President and Chief Executive Officer and principal executive officer on the Start Date; however, Dr. Finney will continue to serve as Chair of the Board.
On March 4, 2024, the Board of Directors (the “Board”) of Vaxart, Inc. (the “Company”) appointed Steven Lo as the Company’s Chief Executive Officer, President, and principal executive officer, as well as a member of the Board, in each case effective as of March 18, 2024 (the “Start Date”).
Max materiality 0.92 · Median 0.68 · Most common event other_material